MiNK Therapeutics, Inc. filings document a clinical-stage biopharmaceutical company focused on allogeneic iNKT cell therapies, including formal disclosures about agenT-797, program updates, operating results and financing activity. Current reports have covered quarterly and annual financial results, clinical and publication-related updates, potential strategic discussions, and an at-the-market common stock sales agreement registered under a shelf registration statement.
The company’s proxy and governance filings disclose annual meeting matters, director elections, auditor ratification, board appointments, officer designations and compensation-related items. Other filings describe its Nasdaq-listed common stock, equity incentive plan activity, intercompany services arrangements with Agenus for finance functions, and risk-sensitive updates related to clinical development, capital needs and public-company governance.
MiNK Therapeutics filed its annual report detailing progress on its allogeneic invariant natural killer T (iNKT) cell therapy platform, led by agenT‑797 in Phase 2 trials for cancer, severe pneumonia-related respiratory failure, and graft-versus-host disease. The company is also advancing engineered CAR‑iNKT programs MiNK‑215 and MiNK‑413 and expanding collaborations to support TCR and RNA technologies. MiNK reported a net loss of $12.5 million for 2025, compared with $10.8 million in 2024, and an accumulated deficit of $156.7 million. As of June 30, 2025, non‑affiliate market value of common stock was $10.9 million, with 4,965,858 shares outstanding as of March 27, 2026, and 15 full‑time employees as of February 28, 2026.
MiNK Therapeutics reported a net loss of $2.6 million, or $0.56 per share, for Q4 2025, versus $2.5 million, or $0.62 per share, in Q4 2024. For full-year 2025, net loss was $12.5 million, or $2.93 per share, compared with $10.8 million, or $2.86 per share, in 2024.
The company ended 2025 with $13.4 million in cash and subsequently raised an additional $3.0 million via an at-the-market program, supporting operations through 2026. MiNK highlighted non-dilutive funding, advancing Phase 2 programs in ARDS and GVHD, and multiple 2026 clinical and scientific catalysts.
MiNK Therapeutics used this report to clarify market speculation about its cell therapy candidate agenT-797. The company states it is in active discussions with multiple parties about potential combination clinical trials for agenT-797 and about possible strategic minority investments in the company.
MiNK emphasizes that these talks reflect outside interest in its allogeneic iNKT cell platform, including for serious conditions such as critical illness, but also makes clear that it has not entered into any binding agreements for trials or investments. Any such deals remain uncertain and subject to risk, as highlighted in its previously filed risk factor disclosures.
MiNK Therapeutics, Inc. filed an initial ownership report for Principal Accounting Officer Austin Charette. The filing shows beneficial ownership of 40 shares of MiNK Therapeutics common stock held directly, with no specific buy or sell transaction reported.
MiNK Therapeutics reported leadership changes in its finance function. Effective March 13, 2026, the board appointed Melissa Orilall, currently Vice President, Global Financial Operations at Agenus Inc., as Principal Financial Officer, and Austin Charette, Senior Director, Financial Reporting and Compliance at Agenus, as Principal Accounting Officer.
Both executives provide services to MiNK through an Amended and Restated Intercompany Services Agreement with Agenus and do not receive compensation directly from MiNK. The company states there were no new or modified arrangements tied to these designations, and neither appointee has disclosable family relationships or related-party transactions with MiNK’s directors or executive officers.
MiNK Therapeutics, Inc. director Barbara Ryan reported open-market sales of 1,500 shares of Common Stock. The transactions occurred on March 9–10, 2026 at prices between 10.1725 and 15.5652 per share. After these sales, she directly holds 20,406 shares of MiNK Therapeutics common stock.
According to the footnote, the shares sold were originally received as compensation for her services on the company’s Board of Directors, indicating the activity relates to monetizing equity-based director compensation rather than exercising options or derivatives.
MiNK Therapeutics, Inc. director Ryan Barbara reported selling a total of 500 shares of common stock in open-market transactions. The sales occurred on February 27, 2026 for 400 shares at $10.8583 per share and on March 2, 2026 for 100 shares at $10.8258 per share. After these trades, Barbara directly owned 21,906 shares of MiNK Therapeutics common stock.
MiNK Therapeutics, Inc. disclosed an amended insider trading report for its chief executive officer. The amendment updates a prior Form 4 to include 10,024 shares of common stock that were withheld on January 2, 2026 to cover withholding taxes related to stock issued to the executive. These shares were not originally shown in Table I of the earlier filing. After this tax withholding transaction at a reported price of $11.12 per share, the executive beneficially owns 57,942 shares of MiNK Therapeutics common stock in direct ownership. The amendment is described as correcting an error in the original Form 4 filed on January 6, 2026.
MiNK Therapeutics, Inc. reported that Chief Executive Officer Jennifer Buell received new equity awards. On January 2, 2026, she was granted 50,000 stock options with an exercise price of $11.12 per share, exercisable over a three-year vesting schedule, with one-third vesting on the one-year anniversary of the grant date and the remainder in eight equal quarterly installments.
On the same date, she also acquired 31,474 shares of common stock as her 2025 performance bonus, valued at $11.12 per share, which was the fair market value on the issuance date. These bonus shares are fully vested but subject to a lockup, with 100% of the award released on February 2, 2026. Following the stock grant, she directly owned 67,966 common shares.
MiNK Therapeutics director Ryan Barbara received a grant of 5,395 stock options on January 2, 2026. The options give the right to buy common stock at an exercise price of $11.12 per share and expire on February 2, 2036. According to the vesting terms, the option vests on February 2, 2026, provided Barbara continues to serve on the company’s board of directors through that date. After this grant, Barbara beneficially owns 5,395 derivative securities directly.